The goal of our lab is to develop cellular immunotherapies that are clinically translated for the treatment of patients with solid cancers. We are focused on interrogating immunosuppressive and heterogenous tumors using patient samples as well as comprehensive preclinical modeling, and leveraging these findings into novel synthetic immune cell engineering approaches and innovative combinatorial immunotherapies that define the next generation of safe and effective cancer treatment strategies.